

10. Fukuchi, Y., Ito, M., Shibata, F., Kitamura, T., and Nakajima, H. (2008) Activation of C/EBPa or PU.1 in hematopoietic stem cells leads to their reduced self-renewal and proliferation. *Stem cells* 26: : 3172-3188.
11. Nakajima, H., Tamura, T., Ito, M., Shibata, F., Kuroda, K., Fukuchi, Y., Watanabe, N., Kitamura, T., Ikeda, Y., and Handa M. (2008) SHD1 is a novel cytokine-inducible, negative feedback regulator of STAT5-dependent transcription. *Blood* 113: 1 027-1036.
12. Islam, S.M., Shinmyo, Y., Okafuji, T., Su, Y., Naser, I.B., Ahmed, G., Zhang, S., Chen, S., Ohta, K., Kiyonari, H., Abe, T., Tanaka, S., Nishinakamura, R., Terashima, T., Kitamura, T., and Tanaka, H. (2009) Draxin, a novel repulsive guidance protein for spinal cord and forebrain commissures. *Science* 323:388-393.
13. Komeno, Y., Kitaura, J. and Kitamura, T. (2009) Molecular bases of myelodysplastic syndromes: Lessons from animal models. *J Cell. Physiol.* in press.
14. Kitamura, T., Oki, T., Watanabe-Okochi, N., Komeno, Y., Kato, N., Yuji, K., Ono, R., Nakajima, H., Tojo, A., Nosaka, T. and Kitaura, J. (2009) Identification of leukemia-related gene alterations: Molecular pathogenesis of leukemia, myeloproliferative disorders (MPD), and myelodysplastic syndromes (MDS). *Blood Cells, Molecules and Diseases* in press.
15. Kawashima, T., Bao, Y.C., Minoshima, Y., Nomura, Y., Hatori, T., Hori, T., Fukagawa, T., Takahashi, N., Nosaka, T., Inoue, M., Sato, T., Kukimoto-Niino, M., Shirouzu, M., Yokoyama, S., and Kitamura, T. (2009) A Rac GTPase activating protein MgcRacGAP is an NLS-containing nuclear chaperone in the activation of STAT transcription factors. *Mol Cell Biol.*, 29:1796-1813.
16. Watanabe-Okochi, N., Oki, T., Komeno, Y., Kato, N., Yuji, K., Ono, R., Harada, Y., Harada, H., Hayashi, Y., Nakajima, H., Nosaka, T., Kitaura, J., and Kitamura, T. (2009) Possible involvement of RasGRP4 in leukemogenesis. *Int J. Hematology*, in press.

17. 北村俊雄、等泰道 (2008) FLT3阻害剤とJAK阻害剤:造血器腫瘍に対するチロシンキナーゼ阻害剤の有効性と開発状況 医学のあゆみ 224:103-107.
 18. 米野由希子、北村俊雄 (2008) 癌幹細胞と遺伝子異常—マウス骨髄移植モデルの有用性 医学のあゆみ 227:67-71.
 19. 沖俊彦、北村俊雄 (2009) iPS細胞と発現ベクター 細胞工学 28:209-214.
 20. 北村俊雄、沖俊彦 (2009) iPS細胞作製におけるウイルスベクターの役割と問題点 臨床検査 53:231-235.
 21. 北村俊雄、渡辺直子、米野由希子、加藤菜穂子、中原史雄、土岐典子、沖俊彦、北浦次郎 (2009) 白血病、骨髄増殖性疾患、骨髄異形成症候群発症の分子メカニズム 臨床血液 印刷中
2. 学会発表
1. 山西吉典、北浦次郎、伊沢久未、沖俊彦、北村俊雄 活性型レセプターLMIR5の機能解析:マウスおよびヒトLMIR5の相違.第4回麒麟塾、口演(2008年7月)
 2. Yamanishi Y, Kitaura J, Izawa K, Matsuoka T, Oki T, Lu Y, Shibata F, Yamazaki S, Kumagai H, Nakajima H, Maeda-Yamamoto M, Tybulewicz V.L, Takai T, and Kitamura T. Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells. The 15th East Asia Joint Conference. (2008年7月)
 3. Komeno Y, Kitaura J, Watanabe-Okochi N, Kato N, Oki T, Honjo T and Kitamura T. Overexpression of AID causes both T and B lymphoma in a mouse BMT model. ISEH 37th Annual Scientific Meeting, Poster Session (2008年7月)
 4. 北村俊雄 白血病、骨髄増殖性疾患、骨髄異形成症候群発症の分子メカニズム. 第70回日本血液学会総会、シンポジウム (2008年10月)
 5. 渡辺(大河内)直子、北浦次郎、原田浩徳、米野由希子、加藤菜穂子、小埜良一、野阪哲哉、中島秀明、北村俊雄 マウス骨髄移植モデルにおいて、Evi1はMDS/AMLを誘発する. 第70回日本血液学会総会、口演 (2008年10月)
 6. 加藤菜穂子、米野由希子、渡辺(大河内)直子、原田浩徳、原田結花、北浦次郎、北村俊雄 AML,MDS でみられた

- C/EBP α 変異体のマウス BMT model.
第 70 回日本血液学会総会、口演(2008 年 10 月)
7. 米野由希子、北浦次郎、渡辺(大河内)直子、加藤菜穂子、沖俊彦、本庶佑、北村俊雄 BMT モデルを用いた AID 高発現による白血病・リンパ腫の解析. 第 70 回日本血液学会総会、口演 (2008 年 10 月)
 8. 川島敏行、土屋秋穂、北村俊雄 新しいメカニズムで JAK/STAT シグナルを抑制する阻害剤の同定. 第 70 回日本血液学会総会、口演 (2008 年 10 月)
 9. 中島秀明、越野裕子、柴田文、福地由美、Dean Li、北村俊雄 Robo4 の造血幹細胞における生理学的機能. 第 70 回日本血液学会総会、ポスター (2008 年 10 月)
 10. 和田妙子、菊池次郎、清水瑠美、北村俊雄、古川雄祐 ヒストン脱アセチル化酵素(HDAC)による血球分化の制御と白血病における過剰発現. 第 70 回日本血液学会総会、ポスター (2008 年 10 月)
 11. 米野由希子、加藤菜穂子、北村俊雄 BMT モデルを用いた AID 高発現による白血病・リンパ腫の解析. 第 67 回日本癌学会学術総会、口演 (2008 年 10 月)
 12. 山西吉典、北浦次郎、伊沢久未、沖俊彦、高井俊行、北村俊雄 可溶性 LMIR5 は LPS による炎症反応を増強する. 第 38 回日本免疫学会総会、口演 (2008 年 12 月)
 13. 榎本豊、北浦次郎、山西吉典、伊沢久未、沖俊彦、高井俊行、北村俊雄 活性化レセプター-LMIR7 の機能解析. 第 38 回日本免疫学会総会、口演 (2008 年 12 月)
 14. 伊沢久未、北浦次郎、山西吉典、松岡孝幸、沖俊彦、高井俊行、北村俊雄 LMIR3 はマスト細胞において細胞内領域の ITIM を介した抑制化シグナルと ITAM を有する FcR γ との会合を介した活性化シグナルを伝達する. 第 38 回日本免疫学会総会、口演 (2008 年 12 月)
 15. 杉内正弘、北浦次郎、山西吉典、伊沢久未、沖俊彦、高井俊行、北村俊雄 活性化レセプターの LMIR6 は末梢血の樹状細胞に高発現する. 第 38 回日本免疫学会総会、ポスター (2008 年 12 月)
 16. 土屋秋穂、川島敏行、北村俊雄 インターロイキン 6(IL-6)阻害剤のスクリーニング法の開発と阻害剤の評価. 第

31回日本分子生物学会年会・第81回
日本生化学会大会 合同大会、ポスタ
ー (2008年12月)

2. 実用新案登録

なし

3. その他

なし

17. Yamanishi Y, Kitaura J, Izawa K,
Oki T, Takai T and Kitamura T.
Analysis of Mouse LMIR5/CLM-7 as
An Activating Receptor: Differential
Regulation of LMIR5/CLM-7 in
Mouse Versus Human Cells. 50th
American Society of Hematology
(ASH) Annual Meeting (2008年12
月)

18. 北村俊雄 Lessons from mouse BMT
models for leukemia, MDS and MPD.
日米血液腫瘍ワークショップ、招待口
演 (2009年3月)

G. 知的財産権の出願・登録状況(予定を 含む)

1. 特許取得

シグナルシーケンストラップ法

特許第3499528号

中外製薬株式会社、北村俊雄

発明者：北村俊雄、小嶋哲郎

パッケージング細胞

特許第3904451号

北村俊雄、中外製薬株式会社

発明者：北村俊雄、森田純代

ユーイング肉腫における新規膜抗原・分泌蛋白の探索

研究分担者 野阪 哲哉 三重大学大学院医学系研究科
感染症制御医学分野 教授

研究要旨

ユーイング肉腫 (Ewing sarcoma) は若年者に好発する骨腫瘍である。化学療法の発達により予後は改善されつつあるが、依然不良であり、早期診断が望まれる。当研究ではシグナルシーケンストラップ法を用いて、ユーイング肉腫に特異的な新規膜抗原や分泌蛋白のスクリーニングを行い、3種の興味深い遺伝子を得た。うち、ひとつの遺伝子はユーイング肉腫患者細胞で全例発現がみられたのに対し、骨肉腫患者細胞では一部の症例のみにみられ、診断への応用が示唆された。

研究分担者 北村 俊雄

東京大学医科学研究所

細胞療法分野 教授

A. 研究目的

ユーイング肉腫は1921年、ユーイングによって報告された高悪性度小円形細胞肉腫で、5-15歳で発症し、骨肉腫よりも若年者に好発する傾向がある。大腿骨、骨盤、肋骨に好発するが、ユーイング肉腫の細胞起源は不明であり、骨の腫瘍であるにもかかわらず軟部への進展が速い。放射線や化学療法に対する反応はよいが、再発しやすく、骨や肺への転移のため、5年生存率は50%程度と悪性度の高い腫瘍である。ユーイング肉腫は、骨を覆っている軟部組織が厚いために早期発見が困難な場合も多く、早期診断と鑑別診断の目的で、ユーイング肉腫特異的な分泌蛋白、膜蛋白を同定することが望まれている。

本研究はそのような腫瘍マーカーとなる分子の探索を目的としており、将来的には分子標的療法への応用も視野に入れている。

B. 研究方法

(レトロウイルスを用いたシグナルシーケンストラップ法によるユーイング肉腫特異的分泌蛋白、膜蛋白遺伝子の同定)

当研究代表者らが開発したシグナルシーケンストラップ法 (Kojima T and Kitamura T, Nat Biotechnol 1999) は、IL-3依存性のマウス血液細胞株 Ba/F3 が活性型 *c-mpl* によってトランスフォームし、IL-3非依存性に増殖するようになる性質を応用したものである。即ち、細胞膜に局在できないように細工した活性型 *c-mpl* 遺伝子との融合遺伝子ライブラリーを作製し、融合遺伝子がシグナルシーケンスを有する場合にのみ、活性型 *c-mpl* 遺伝子が細胞膜に移行し、Ba/F3細胞をトランスフォームすることを利用して、シグナルシーケンをもつ遺伝子を単離するという原理である。ライブラリーの作製に用いる mRNA が由来する細胞を選択することにより、組織特異的な分泌蛋白、膜蛋白遺伝子を単離することが可能となる。研究分担者らはユーイン

グ肉腫由来のヒト細胞株 (SJES-2, SJES-3, SJES-5, SJES-6, SJES-7, SJES-8) を用いて、各々から mRNA を抽出し、それらを等量ずつ混合し、そこからシグナルシークエンストラップ用のライブラリーを作製し、Ba/F3 細胞でスクリーニングを行った。得られたクローンからゲノム DNA を抽出し、ライブラリーの作製に用いたベクター特異的配列を primer にした PCR を行い、増幅された DNA の塩基配列を決定した。ユーイング肉腫の細胞起源に関する定説はないが、得られたクローンのうち、興味深い遺伝子 3 種に関して、まず、当該遺伝子の正常組織での発現パターンを RT-PCR で調べた。次に、最も興味深いと考えた遺伝子に関して、細胞株、患者病変組織における当該遺伝子の発現を免疫組織染色で解析し、同時に患者細胞における RNA 発現も解析した。また、ユーイング肉腫において頻繁に観察される *EWS-FLI1* 融合遺伝子の発現が当該遺伝子の発現に及ぼす影響についても siRNA を用いて解析した。

(倫理面への配慮)

当研究は、三重大学の研究倫理委員会の承認を得ている (No 1002)。臨床検体を用いる解析に関しては、その指針に従って該当者に説明を行い、同意書に署名をいただいた後、研究を行う。

C. 研究結果

レトロウイルス発現系を用いたシグナルシークエンストラップ法にて 81 種類 257 クロオンが単離された。(Table1) これらのうち、明らかに組織特異性のない遺伝子や、他の組織の癌細胞で強く発現されているものは除外し、興味深い組織特異的 mRNA 発現パターンを示す 3 遺伝子に焦点を絞ってさらに解析した。遺伝子 A は分泌蛋白であり、正常マウス組織で

は脳において特異的に強く発現し、ヒト間葉系幹細胞での発現は検出されなかった。腫瘍細胞株では神経芽腫、横紋筋肉腫、Ewing 肉腫由来のもので mRNA の強い発現が検出された。遺伝子 B は膜蛋白であり、正常マウス組織では脳において強く発現しており、他に脾、胸腺、骨髄、精巣、筋肉で発現がみられ、ヒト間葉系幹細胞での発現は検出されなかった。腫瘍細胞株では横紋筋肉腫、Ewing 肉腫由来のもので mRNA の強い発現が検出された。遺伝子 C は膜蛋白であり、正常マウスの様々な組織で発現していたが、ヒト間葉系幹細胞での発現は検出されなかった。腫瘍細胞株では Ewing 肉腫由来のもので mRNA の強い発現が検出された。

遺伝子 A に関して、細胞株における当該遺伝子の蛋白レベルでの発現を免疫組織化学染色法にて解析したところ、骨肉腫との比較において、ユーイング肉腫特異的発現が観察された。同時に患者細胞における RNA 発現も RT-PCR にて解析したところ、同様の結果が得られた (骨肉腫 2/13 症例で陽性、ユーイング肉腫 7/7 症例で陽性)。ユーイング肉腫患者病変組織を用いた免疫組織化学染色でも遺伝子 A の発現が観察された。また、ユーイング肉腫細胞株において *EWS-FLI1* 融合遺伝子の発現を siRNA を用いてノックダウンしたところ、コントロールの遺伝子発現に比較して、遺伝子 A の発現が有意に低下した。

Table1. レトロウイルスを用いたシグナルシークエンストラップ法により単離された遺伝子。左端の数字は得られた頻度。

22	<u>NM_002087.</u>	Homo sapiens granulin (GRN). mRNA
16	<u>NM_201414.</u>	Homo sapiens amyloid beta (A4) precursor protein (peptidasenexin-II. Alzheimer disease) (APP). transcript variant3. mRNA
	<u>NM_201413.</u>	Homo sapiens amyloid beta (A4) precursor protein (peptidasenexin-II. Alzheimer disease) (APP). transcript variant2. mRNA
	<u>NM_000484.</u>	Homo sapiens amyloid beta (A4) precursor protein (peptidasenexin-II. Alzheimer disease) (APP). transcript variant1. mRNA

- 14 NM 000918. Homo sapiens procollagen-proline, 2-oxoglutarate 4-dioxygenase(proline 4-hydroxylase), beta polypeptide (P4HB). mRNA
- 12 NM 173614. Homo sapiens NODAL modulator 2 (NOMO2). transcript variant 2. mRNA
NM 00100406 Homo sapiens NODAL modulator 2 (NOMO2). transcript variant 1. mRNA
0.
- 12 NM 014287 Homo sapiens NODAL modulator 1 (NOMO1). mRNA
- 11 NM 00100406 Homo sapiens NODAL modulator 3 (NOMO3). mRNA
7.
- 10 NM 012201. Homo sapiens golgi apparatus protein 1 (GLG1). mRNA
- 6 NM 00101811 Homo sapiens podocalyxin-like (PODXL). transcript variant 1. mRNA
1.
- NM 005397. Homo sapiens podocalyxin-like (PODXL). transcript variant 2. mRNA
- 6 NM 013995. Homo sapiens lysosomal-associated membrane protein 2 (LAMP2).transcript variant LAMP2B. mRNA
NM 002294. Homo sapiens lysosomal-associated membrane protein 2 (LAMP2).transcript variant LAMP2A. mRNA
- 6 NM 000598. Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3).transcript variant 2. mRNA
- 6 NM 198589. Homo sapiens basigin (Ok blood group) (BSG). transcript variant 2.mRNA
- 6 NM 004393. Homo sapiens dystroglycan 1 (dystrophin-associated glycoprotein 1)(DAG1). mRNA
- 5 NM 015393 Homo sapiens DKFZP564O0823 protein. mRNA
- 4 NM 001962. Homo sapiens ephrin-A5 (EFNA5). mRNA
- 4 NM 003118. Homo sapiens secreted protein, acidic, cysteine-rich (osteonectin)(SPARC). mRNA
- 4 NM 00102516 Homo sapiens CD97 molecule (CD97). transcript variant 3. mRNA
0
- NM 078481. Homo sapiens CD97 molecule (CD97). transcript variant 1. mRNA
- 4 NM 004343. Homo sapiens calreticulin (CALR). mRNA
- 4 NM 001552. Homo sapiens insulin-like growth factor binding protein 4 (IGFBP4).mRNA
- 3 NM 006505. Homo sapiens poliovirus receptor (PVR). mRNA
- 3 NM 002998. Homo sapiens syndecan 2 (heparan sulfate proteoglycan 1. cellsurface-associated, fibroglycan) (SDC2). mRNA
- 3 NM 201575. Homo sapiens seizure related 6 homolog (mouse)-like 2 (SEZ6L2).transcript variant 2. mRNA
NM 012410. Homo sapiens seizure related 6 homolog (mouse)-like 2 (SEZ6L2).transcript variant 1. mRNA
- 3 NM 025240. Homo sapiens CD276 molecule (CD276). transcript variant 2. mRNA
NM 00102473 Homo sapiens CD276 molecule (CD276). transcript variant 1. mRNA
6.
- 3 NM 181836. Homo sapiens transmembrane emp24 protein transport domaincontaining 7 (TMED7). mRNA
- 3 NM 002951. Homo sapiens ribophorin II (RPN2). mRNA
- 3 NM 000271. Homo sapiens Niemann-Pick disease, type C1 (NPC1). mRNA
- 3 NM 018475. Homo sapiens transmembrane protein 165 (TMEM165), mRNA.
- 3 NM 005514. Homo sapiens mRNA for MHC class I antigen (HLA-B gene).
- 3 NM 000758. Homo sapiens colony stimulating factor 2 (granulocyte-macrophage)(CSF2). mRNA
- 2 NM 002507. Homo sapiens nerve growth factor receptor (TNFR superfamily, member16) (NGFR). mRNA
- 2 NM 002950 Homo sapiens ribophorin I (RPN1). mRNA
- 2 NM 207351 Homo sapiens proline-rich transmembrane protein 3 (PRRT3). mRNA
- 2 NM 203339 Homo sapiens clusterin (CLU). transcript variant 2. mRNA
- 2 NM 002778. Homo sapiens prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) (PSAP), mRNA
- 2 遺伝子 B
- 2 NM 005561. Homo sapiens lysosomal-associated membrane protein 1 (LAMP1). mRNA
- 2 NM 00100412 Homo sapiens quiescin Q6 (QSCN6). transcript variant 2. mRNA
8.
- NM 002826 Homo sapiens quiescin Q6 (QSCN6). transcript variant 1. mRNA

- 2 NM 017455. Homo sapiens neuroplastin (NPTN). transcript variant alpha. mRNA
- 2 NM 002901. Homo sapiens reticulocalbin 1. EF-hand calcium binding domain(RCN1). mRNA
- 2 NM 031935. Homo sapiens hemicentin 1 (HMCN1). mRNA
- 2 NM 004995. Homo sapiens matrix metalloproteinase 14 (membrane-inserted)(MMP14). mRNA
- 2 NM 001848 Homo sapiens collagen. type VI. alpha 1 (COL6A1). mRNA
- 2 NM 000247. Homo sapiens MHC class I polypeptide-related sequence A (MICA).mRNA
- 2 NM 002332. Homo sapiens low density lipoprotein-related protein 1(alpha-2-macroglobulin receptor) (LRP1). mRNA
- 2 NM 052932. Homo sapiens transmembrane protein 123 (TMEM123). mRNA
- 2 NM 001855. Homo sapiens collagen. type XV. alpha 1 (COL15A1). mRNA
- 2 NM 005373 Homo sapiens myeloproliferative leukemia virus oncogene (MPL). mRNA
- 2 NM 002743. Homo sapiens protein kinase C substrate 80K-H (PRKCSH). transcriptvariant 1. mRNA
- NM 00100132 Homo sapiens protein kinase C substrate 80K-H (PRKCSH). transcriptvariant 9. mRNA
- 2 NM 152920. Homo sapiens egf-like module containing. mucin-like. hormonereceptor-like 2 (EMR2). transcript variant 6. mRNA
- NM 152916. Homo sapiens egf-like module containing. mucin-like. hormonereceptor-like 2 (EMR2). transcript variant 2. mRNA
- NM 152919. Homo sapiens egf-like module containing. mucin-like. hormonereceptor-like 2 (EMR2). transcript variant 5. mRNA
- 2 NM 000089. Homo sapiens collagen. type I. alpha 2 (COL1A2). mRNA
- 2 NM 005567. Homo sapiens lectin. galactoside-binding. soluble. 3 bindingprotein (LGALS3BP). mRNA
- 1 NM 130440. Homo sapiens protein tyrosine phosphatase. receptor type. F(PTPRF). transcript variant 2. mRNA
- 1 NM 001901 Homo sapiens connective tissue growth factor (CTGF). mRNA
- 1 NM 004911 Homo sapiens protein disulfide isomerase family A. member 4(PDIA4). mRNA
- 1 NM 005545. Homo sapiens immunoglobulin superfamily containing leucine-richrepeat (ISLR). transcript variant 1. mRNA
- 1 NM 000088 Homo sapiens collagen, type I, alpha 1 (COL1A1), mRNA
- 1 NM 002593. Homo sapiens procollagen C-endopeptidase enhancer(PCOLCE) . mRNA
- 1 NM 017860. Homo sapiens chromosome 1 open reading frame 56 (C1orf56). mRNA
- 1 NM 003254. Homo sapiens TIMP metalloproteinase inhibitor 1 (TIMP1). mRNA
- 1 NM 000599. Homo sapiens insulin-like growth factor binding protein 5 (IGFBP5).mRNA
- 1 NM 000094. Homo sapiens collagen. type VII. alpha 1 (epidermolysis bullosa.dystrophic. dominant and recessive) (COL7A1). mRNA
- 1 NM 024959. Homo sapiens solute carrier family 24 (sodium/potassium/calciumexchanger). member 6 (SLC24A6). mRNA
- 1 NM 004540. Homo sapiens neural cell adhesion molecule 2 (NCAM2). mRNA
- 1 NM 000093. Homo sapiens collagen. type V. alpha 1 (COL5A1). mRNA
- 1 NM 020404. Homo sapiens CD248 molecule. endosialin (CD248). mRNA
- 1 NM 004107. Homo sapiens Fc fragment of IgG, receptor, transporter, alpha(FCGRT), mRNA
- 1 NM 006184. Homo sapiens nucleobindin 1 (NUCB1). mRNA
- 1 NM 139072 Homo sapiens delta-notch-like EGF repeat-containing transmembrane(DNER). mRNA
- 1 NM 002338 Homo sapiens limbic system-associated membrane protein (LSAMP).mRNA
- 1 NM 002317. Homo sapiens lysyl oxidase (LOX). mRNA
- 1 遺伝子 C
- 1 AY738975. Homo sapiens isolate Tor36(ZE657) mitochondrion. complete genome
- 1 NM 005570. Homo sapiens lectin. mannose-binding. 1 (LMAN1). mRNA
- 1 NM 031462. Homo sapiens CD99 molecule-like 2 (CD99L2). transcript variant 1.mRNA
- NM 134446 Homo sapiens CD99 molecule-like 2 (CD99L2). transcript variant 2.mRNA
- 1 NM 005711 Homo sapiens EGF-like repeats and discoidin I-like domains 3(EDIL3). mRNA
- 1 NM 022464 Homo sapiens SIL1 homolog. endoplasmic reticulum chaperone (S.cerevisiae) (SIL1). transcript variant 2. mRNA
- 1 遺伝子 A
- 1 NM 032348. Homo sapiens matrix-remodelling associated 8 (MXRA8). mRNA

- 1 NM_000094. Homo sapiens collagen, type VII, alpha 1 (epidermolysis bullosa dystrophica, dominant and recessive) (COL7A1). mRNA
- 1 NM_006404. Homo sapiens protein C receptor, endothelial (EPCR) (PROCR). mRNA
- 1 NM_00103228. Homo sapiens tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI). transcript variant 2. mRNA
- 1 NM_001235. serpin peptidase inhibitor, clade H (heat shock protein 47), member 1. (collagen binding protein 1) (SERPINH1)

D. 考察

上記の予備的実験結果では、遺伝子 A の発現が見られないときは、ユーイング肉腫の可能性が低いと言えそうである。これは、骨肉腫との鑑別診断に役立つと思われる。遺伝子 A は分泌蛋白であるので、今後、血清を用いた ELISA 法による検出が可能になれば、疾患特異性、予後との関連など、腫瘍マーカーになりうるか、明らかになってくるであろう。現在、上記 3 遺伝子産物に対するモノクローナル抗体を作製中であるが、有用な抗体の開発とともに、ELISA による検出法の開発も重要となってくる。さらに、上記遺伝子がユーイング肉腫の病因・病態にも直接関与するのか、明らかにする必要がある。また、*EWS-FLI1* 融合遺伝子産物が直接に遺伝子 A の発現を調節しているのか、も今後の検討課題である。

E. 結論

レトロウイルス発現クローニング法を用いたシグナルシーケンストラップ法にて 6 種のユーイング肉腫細胞株 mRNA の混合物から、81 種、257 クローンの遺伝子を単離し、特に 3 種の遺伝子に関して、現在解析中である。うち、ひとつの遺伝子はユーイング肉腫と骨肉腫の鑑別診断に応用できる可能性が示唆された。

F. 研究発表

1. 論文発表

1) Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T, Kitamura T. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. *Blood* 111: 4297-4308, 2008.

2) Nishio M, Ohtsuka J, Tsurudome M, Nosaka T, Kolakofsky D. Human parainfluenza virus type

2 V protein inhibits genome replication by binding to the L protein; a possible role in promoting viral fitness. *J Virol* 82 : 6130-6138, 2008.

3) Matsushita H, Nakajima H, Nakamura Y, Tsukamoto H, Tanaka Y, Jin G, Yabe M, Asai S, Ono R, Nosaka T, Sugita K, Morimoto A, Hayashi Y, Hotta T, Ando K, Miyachi H. C/EBP α and C/EBP ϵ induce the monocytic differentiation of myelomonocytic cells with the *MLL*-chimeric fusion gene. *Oncogene* 27 : 6749-6760, 2008.

4) Ikeya M, Nosaka T, Fukushima K, Kawada M, Furuta Y, Kitamura T, Sasai Y. *Twisted gastrulation* mutation suppresses skeletal defect phenotypes in *Crossveinless 2* mutant mice. *Mech Dev* 125 : 832-842, 2008.

5) Hiwatari M, Ono R, Taki T, Hishiya A, Ishii E, Kitamura T, Hayashi Y, Nosaka T. Novel gain-of-function mutation in the extracellular domain of the *PDGFRA* gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23). *Leukemia* 22 : 2279-2280, 2008.

6) Kawashima T, Bao YC, Minoshima Y, Nomura Y, Hatori T, Hori T, Fukagawa T, Fukada T, Takahashi N, Nosaka T, Inoue M, Sato T, Kukimoto-Niino M, Shirouzu, M, Yokoyama S, Kitamura T. A Rac GTPase activating protein MgcRacGAP is an NLS-containing nuclear

chaperone in the activation of STAT transcription factors. Mol Cell Biol 29 :1796-1813, 2009.

7) 野阪哲哉. 造血器腫瘍マウスモデル. がん分子標的治療. 6(2):25-33(101-109), 2008.

2. 学会発表

1) 渡辺（大河内）直子、北浦次郎、原田浩徳、米野由希子、加藤菜穂子、小埜良一、野阪哲哉、中島秀明、北村俊雄. (2008年10月) マウス骨髄移植モデルにおいて、Evi1 は MDS/AML を誘発する. 第70回日本血液学会総会.

G. 知的財産権の出願・登録状況(予定を含む)

1. 特許取得
なし

2. 実用新案登録
なし

3. その他
なし

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
該当なし							

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
山西 吉典	Analysis of mouse LMIR5/CLM7 as an activating receptor: differential regulation of LMIR5/CLM7 between mouse and human.	Blood	111	688-698	2008
渡辺(大河内) 直子	AML1 mutations induced MDS and MDS/AML in a mouse BMT model.	Blood	111	4297-4308	2008
川島 敏行	A Rac GTPase activating protein MgcRacGAP is an NLS-containing nuclear chaperone in the activation of STAT transcription factors.	Mol Cell Biol.	29	1796-1813	2009

Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells

Yoshinori Yamanishi,¹ Jiro Kitaura,¹ Kumi Izawa,¹ Takayuki Matsuoka,¹ Toshihiko Oki,¹ Yang Lu,¹ Fumi Shibata,¹ Satoshi Yamazaki,² Hidetoshi Kumagai,¹ Hideaki Nakajima,¹ Mari Maeda-Yamamoto,³ Victor L. J. Tybulewicz,⁴ Toshiyuki Takai,⁵ and Toshio Kitamura¹

¹Division of Cellular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan; ²Laboratory of Stem Cell Therapy, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan; ³National Institute of Vegetable and Tea Science, National Agriculture Research Organization, Shizuoka, Japan; ⁴Division of Immune Cell Biology, National Institute for Medical Research, London, United Kingdom; and ⁵Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

We have analyzed leukocyte mono-Ig-like receptor 5 (LMIR5) as an activating receptor among paired LMIRs. Mouse LMIR5 (mLMIR5) is expressed in myeloid cells such as mast cells, granulocytes, macrophages, and dendritic cells. Cross-linking of transduced mLMIR5 in bone marrow-derived mast cells (BMMCs) caused activation events, including cytokine production, cell survival, degranulation, and adhesion to the extracellular matrix. mLMIR5 associated with DAP12 and to a lesser extent with DAP10, and mLMIR5-mediated functions of BMMCs

were strongly inhibited by DAP12 deficiency. Importantly, cross-linking of endogenous mLMIR5 induced dependent activation of fetal liver-derived mast cells. Unlike mLMIR5, cross-linking of human LMIR5 (hLMIR5) induced cytokine production of BMMCs even in the absence of both DAP12 and DAP10, suggesting the existence of unidentified adaptors. Interestingly, hLMIR5 possessed a tyrosine residue (Y188) in the cytoplasmic region. Signaling via Y188 phosphorylation played a predominant role in hLMIR5-mediated cytokine pro-

duction in DAP12-deficient, but not wild-type BMMCs. In addition, experiments using DAP10/DAP12 double-deficient BMMCs suggested the existence of Y188 phosphorylation-dependent and -independent signals from unidentified adaptors. Collectively, although both mouse and human LMIR5 play activatory roles in innate immunity cells, the functions of LMIR5 were differentially regulated in mouse versus human cells. (Blood. 2008;111:688-698)

© 2008 by The American Society of Hematology

Introduction

It is widely accepted that mast cells are major effector cells in allergic inflammation through a high-affinity IgE receptor (FcεRI). However, recent advances have delineated the significant roles of mast cells in both innate and adaptive immune responses.¹⁻⁴

To find a novel immune receptor expressed on mast cells, we previously performed a signal sequence trap based on retrovirus-mediated expression screening (SST-REX).⁵ In this screening, we isolated a cDNA for a novel immune receptor, leukocyte mono-Ig-like receptor 1 (LMIR1),⁶ using cDNA library of bone marrow-derived mast cells (BMMCs). Successively, other members of the LMIR family were cloned by searching for sequences homologous with the Ig-like domain of LMIR1. We and others have demonstrated that LMIR1/CMRF-35-like Ig-like molecule-8 (CLM-8)/myeloid-associated Ig-like receptor-1 (MAIR-1)/CD300a and LMIR2/CLM-4/MAIR-II/dendritic cell-derived Ig-like receptor 1 (DIgR1)/CD300d as well as LMIR3/CLM-1 and LMIR4/CLM-5 were a pair of inhibitory and activating, respectively, receptors with high homology in the Ig-like domain.⁶⁻¹⁴ LMIR/CLM forms a family of paired receptors mainly expressed in myeloid cells.⁶⁻¹⁴ In general, activating receptors do not contain any signaling motifs in the short cytoplasmic tails, but transmit signals by associating with immunoreceptor tyrosine-based activation motif (ITAM) or the

related activating motif-bearing molecules via a positively charged residue in the transmembrane domain.¹⁵⁻¹⁹ In the present study, we cloned a cDNA for mouse LMIR5 (mLMIR5)/CLM-7 from a BMMC cDNA library. Analysis of DAP10-, DAP12-, and Fcγ-deficient BMMCs demonstrated the predominant role of DAP12 in the activating functions of mLMIR5.

Structural differences in immune receptors in mouse versus human cells sometimes result in differing immunologic responses. For example, human NKG2D associates only with DAP10. On the other hand, mouse NKG2D has 2 splice variants, where the long isoform (NKG2D-L) associates exclusively with DAP10 and the short isoform (NKG2D-S) associates with both DAP10 and DAP12.²⁰⁻²³ Interestingly, human LMIR5 (hLMIR5)/CD300b/immune receptor expressed by myeloid cell-3 (IREM-3),²⁴ but not mLMIR5, contained a putative tyrosine phosphorylation motif (YXN) in its short cytoplasmic tail. The present results indicated that DAP12 plays a primary role in functions of mLMIR5, while both DAP12 and DAP10 play roles in functions of its human counterpart hLMIR5. Consistent with a recent report by Martinez-Barriocanal and Sayos,²⁴ our results also implicated an unidentified adaptor in the hLMIR5-mediated signaling pathway, which was activated through phosphorylation of the tyrosine in the absence of DAP12. In addition, the experiment using DAP12-deficient and

Submitted April 16, 2007; accepted September 18, 2007. Prepublished online as *Blood* First Edition paper, October 10, 2007; DOI 10.1182/blood-2007-04-085787.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2008 by The American Society of Hematology

DAP10/DAP12 double-deficient BMMCs revealed Y188 phosphorylation-dependent and -independent signals downstream of hLMIR5.

Methods

Cells

Murine cell lines used in this study were as follows: FDC-P1, J774-1, RAW264.7, M1, L-G, 32Dcl3, P815, MC/9, L8057, Ba/F3, WEHI231, A20, EL4, BW5147, and DC2.4. L8057 and DC2.4 were a kind gift from Dr Y. Hirabayashi (National Institute of Health Sciences, Tokyo, Japan) and Dr K. L. Rock (University of Massachusetts Medical School, Worcester, MA), respectively. Peripheral blood (PB) cells, bone marrow (BM) cells, splenocytes, thymocytes, and peritoneal cells derived from C57BL/6 mice (or CBA/J mice) were purified as described.¹⁴ CBA/J mice or C57BL/6J mice (Charles River Laboratories Japan, Yokohama, Japan) were used at 8 to 10 weeks of age for isolation of tissues and cells. All procedures were approved by an institutional review committee. BMMCs or fetal liver mast cells (FLMCs) were generated and cultured as described.²⁵⁻²⁷ BM-derived macrophage (BMMΦ), BM-derived myeloid dendritic cells (BMmDCs), and BM-derived plasmacytoid dendritic cells (BMpDCs) were cultured as described.¹⁴ The following mutant mice were used: *DAP10*^{-/-},²⁰ *DAP12*^{-/-},²⁸ *FcRγ*^{-/-},²⁹ and *Syk*^{+/-}.³⁰

Antibodies and other reagents

Cytokines and anti-mLMIR5 polyclonal antibody (Ab) was obtained from R&D Systems (Minneapolis, MN). Fluorescein isothiocyanate (FITC)-conjugated anti-mouse B220, CD3, CD11b, and Gr-1 mAb were purchased from eBioscience (San Diego, CA). FITC-conjugated anti-mouse IgE, FITC-conjugated anti-mouse Ig polyclonal Ab, R-phycoerythrin (PE)-conjugated anti-mouse c-Kit mAb, and mouse antitrinitrophenyl (TNP) IgE (C38-2) were from BD Pharmingen (San Diego, CA). Anti-Flag mAb (M2), mouse IgG1 mAb (MOPC21), goat IgG polyclonal Ab, and mouse antindinitrophenyl (DNP) IgE mAb (SPE-7) were from Sigma-Aldrich (St Louis, MO). Donkey PE-conjugated F(ab')₂ anti-goat IgG Ab was from Jackson ImmunoResearch Laboratories (West Grove, PA). Anti-Myc mAb (9E10) was from Roche Diagnostics (Indianapolis, IN). Rabbit anti-mouse DAP12 polyclonal Ab was a kind gift from Dr N. Aoki (Asahikawa Medical College, Asahikawa, Japan). Mouse antiphosphotyrosine mAb (4G10) was purchased from Upstate Biotechnology (Charlottesville, VA), and other phospho-specific Abs were from Cell Signaling Technology (Beverly, MA). Other Abs were from Santa Cruz Biotechnology (Santa Cruz, CA). Bovine serum fibronectin (FN), human plasma fibrinogen (FB), and N-glycosidase F were purchased from Sigma-Aldrich, Chemicon (Temecula, CA), and New England Biolabs (Beverly, MA), respectively.

Gene expression analysis

Expression of mLMIR5 was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) as described.¹⁴ Amplification of mLMIR5 as well as β-actin for normalization was performed with the following primers: 5'-TTACCATGGAGATGCTCAGG-3' (base: 266-285) and 5'-TCGCTACAGAGATGTGTCTCC-3' (base: 590-569) for mLMIR5; and 5'-CATCAC-TATTGGCAACGAGC-3' and 5'-ACGACGCTCAGTAACAGTCC-3' for β-actin. Relative expression levels of DAP10, DAP12, and FcRγ among samples were measured by real-time RT-PCR. cDNA was amplified using a LightCycler FastStart DNA Master SYBR Green 1 kit (Roche Diagnostics, Mannheim, Germany) under the following conditions: 1 cycle of 95°C for 10 seconds, 40 cycles of 95°C for 5 seconds, and 60°C for 20 seconds. All samples were independently analyzed 3 times. The following primers were used: 5'-CCCCCAGGCTACCTCC-3' and 5'-TGACATGACCGCATCT-GCA-3' for DAP10; 5'-CAAGATGCGACTGTTCTTCCG-3' and 5'-GGTCTTGACCCCTGAAGCTCC-3' for DAP12; 5'-GCCGTGATCTGT-TCTTGCTC-3' and 5'-CTGCCCTTCGGACCTGGAT-3' for FcRγ; and 5'-ATGTGTCCGTCGTGGATCTGA-3' and 5'-TTGAAGTCGAG-GAGACAACC-3' for GAPDH. Relative gene expression levels were

calculated using standard curves generated by serial dilutions of cDNA and normalized by a GAPDH expression level. Product quality was checked by melting curve analysis via LightCycler software (Roche Diagnostics).

DNA constructs

The GenBank/European Molecular Biology Laboratory (EMBL³¹)/DNA Data Bank of Japan (DDBJ³²) database was searched by using the amino acid sequence of the Ig-like domain of mLMIR1. Based on the sequence data, cDNA of mouse and human LMIR5 were isolated by PCR from a cDNA library of BMMCs (derived from CBA/J or B57BL/6 mice) and a cDNA library of human peripheral mononuclear cells (PMCs), respectively, and confirmed by sequencing as described.⁶ The cDNA fragment of mLMIR5 or hLMIR5, lacking the signal sequence, was tagged with an Flag or Myc epitope at the N terminus. The resultant Flag or Myc-mLMIR5 or hLMIR5 was subcloned into a pME18s vector containing a SLAM signal sequence (a gift from Hisashi Arase, Osaka University, Osaka, Japan)³³ to generate pME-Flag, Myc-mLMIR5, or hLMIR5. The resultant SLAM signal sequence-Flag, Myc-mLMIR5, or hLMIR5 was subcloned into a pMXs-IRES-puro³ (pMXs-IP)³⁴ retroviral vector to generate pMXs-Flag or Myc-mLMIR5 or hLMIR5-IP. Two-step PCR mutagenesis was performed in the replacement of K158 (lysine with a positive charge) of hLMIR5 with Q (glutamine with a neutral charge) and Y188 of hLMIR5 with F (phenylalanine).

Transfection and infection

Retroviral transfection was as described.^{6,34} Briefly, retroviruses were generated by transient transfection of PLAT-E packaging cells³⁵ with FuGENE 6 (Roche Diagnostics). BM cells, BMMCs, or Ba/F3 cells were infected with retroviruses in the presence of 10 μg/mL polybrene. After 48 hours, cell selection was started with appropriate antibiotics.³⁴

Flow cytometry

Cells were stained as described.¹⁴ Flow cytometric analysis was performed with FACSCalibur (BD Biosciences, Mountain View, CA) equipped with CellQuest software and FlowJo software (Tree Star, Ashland, OR). For mLMIR5 staining, cells were incubated with 20 μg/mL anti-mLMIR5 polyclonal Ab or goat polyclonal IgG Ab as control, before incubation with 10 μg/mL PE-conjugated anti-goat IgG F(ab')₂ Ab.

Immunoprecipitation and Western blotting

Cells were lysed with NP-40 lysis buffer containing protease and phosphatase inhibitor cocktail (Sigma-Aldrich). Cell lysates were assayed using a protein assay kit (Bio-Rad, Hercules, CA). Immunoprecipitation and Western blotting were performed as described.¹⁴

Measurement of cytokines and histamines and adhesion assay

BMMCs and FLMCs were stimulated with either 20 μg/mL anti-mLMIR5 Ab, 20 μg/mL control IgG, or 100 nM phorbol-12-myristate-13-acetate (PMA). BMMCs transduced with a Flag-tagged hLMIR5 were stimulated with 20 μg/mL anti-Flag mAb or 20 μg/mL control IgG. In some experiments, BMMCs sensitized with 1 μg/mL anti-TNP IgE for 12 hours were stimulated with 100 ng/mL TNP-BSA, TNF-α, IL-6, and MCP-1 concentrations in culture supernatants were measured using enzyme-linked immunosorbent assay (ELISA) kits (BD Pharmingen and R&D Systems). Histamine released during a 50-minute incubation period was measured as described.²⁵ Adhesion assay was described previously.²⁶

Statistical analysis

Data are shown as means plus or minus standard deviation (SD), and statistical significance was determined by the Student *t* test with *P* levels less than .05 as statistically significant.




Figure 1. Molecular characteristics and gene expression of LMIR5. (A) Alignment of amino acid sequences for mLMIR5 and hLMIR5. CBA and B6 indicate CBA/J mice and C57BL/6 mice, respectively. *Identical amino acids in mLMIR5 and hLMIR5. The putative signal sequence is shown in lower case. The variable type Ig-like domain is underlined; the potential N-linked glycosylation site is boxed. The transmembrane domain is marked by an arrow; the positive-charged amino acid residue (lysine) in the transmembrane domain is circled. Y188 in the cytoplasmic tail of hLMIR5 is shaded. (B) The phylogenetic tree of LMIR1/2/3/4/5 is shown based on homology with the Ig-like domain. Percentage of identity in amino acid sequences of the Ig-like domain was indicated. (C) Lysates of Ba/F3 cells transduced with either a Flag-tagged mLMIR5, a Flag-tagged hLMIR5, or mock were immunoprecipitated with anti-Flag mAb. The precipitates treated with or without N-glycosidase F were immunoblotted with anti-Flag mAb. (D-F) RT-PCR analysis on mLMIR5 expression in murine tissues (D), hematopoietic cell lines (E), and primary hematopoietic cells (F). Specific primers were used for mLMIR5 or β-actin as control. Vertical lines have been inserted to indicate a repositioned gel lane.

Results

Structure of mLMIR5

To identify other members of LMIR besides LMIR1/2,⁶ we searched the database from GenBank/EMBL/DBJ by using the sequence encoding the Ig-like domain of LMIR1/CLM-8. Based on this, we identified and cloned mLMIR5/CLM-7 in addition to another pair, LMIR3/CLM-1 and LMIR4/CLM-5, from a BMMC cDNA library. An Ig-like domain of mLMIR5 shared 34% and 53% identity at amino acid sequences with that of LMIR1 and LMIR3, respectively (Figure 1A,B).⁶ We also cloned its human ortholog from a human PMC cDNA library and found that hLMIR5 shared a 55% identity at overall amino acid sequences with mLMIR5 (Figure 1A). The sequence analysis revealed that mLMIR5 and hLMIR5 are identical to CLM-7^{8,9} and IREM-3,²⁴ respectively. Because hLMIR5/IREM-3 has been recently characterized, we analyzed the structure and functions of mLMIR5/CLM-7 to compare them with those of hLMIR5/IREM-3. mLMIR5 was a type I transmembrane protein composed of an N-terminal signal peptide, an extracellular domain containing a single V-type Ig domain, a transmembrane domain with a positively charged amino acid (lysine), and a short cytoplasmic tail without any signaling

motif (Figure 1A). mLMIR5 protein derived from CBA/J mice or B57BL/6 mice was 209 aa or 204 aa, respectively, in length, because the latter was devoid of 5 aa in its cytoplasmic tail. We thereafter used CBA/J mouse-derived LMIR5 as mLMIR5 unless otherwise stated. Interestingly, mLMIR5 does not harbor a putative tyrosine phosphorylation site in the cytoplasmic region (Figure 1A), which is found in hLMIR5.²⁴


Next, to examine the characteristics of mLMIR5 at protein levels, we generated Ba/F3 cells expressing either a Flag-tagged mLMIR5 or hLMIR5. Western blot analysis using anti-Flag mAb detected mLMIR5 as a major broad band (26–35 kDa) and a faint band (approximately 24 kDa), while hLMIR5 was detected as a broad band (27–30 kDa) and a discrete band (approximately 22 kDa) (Figure 1C). Treatment with N-glycosidase F diverted the apparent molecular mass of mLMIR5, but not hLMIR5, to several bands ranging from 22 to 26 kDa in size. This was consistent with the presence of a putative N-linked glycosylation site in the extracellular domain of mLMIR5, but not hLMIR5 (Figure 1A,C), suggesting that mLMIR5 was an N-glycoprotein.

mLMIR5 is expressed in myeloid lineage cells

To determine the tissue distribution of mLMIR5, we performed RT-PCR analysis and thereby demonstrated that mLMIR5 was

Figure 2. Cell-surface expression of mLMIR5.

(A) Ba/F3 cells transduced with a Flag-tagged mLMIR5 or mock were stained with FITC-conjugated mouse IgG1 or anti-Flag Ab as well as polyclonal goat IgG or anti-mLMIR5 Ab, followed by PE-conjugated anti-goat IgG F(ab')₂. (B) Analysis of mLMIR5 expression on hematopoietic cells derived from C57BL/6 mice. Single-cell suspensions were prepared from BM, PB, peritoneal cavity, and thymus. Cells were stained with control IgG or anti-mLMIR5 Ab followed by PE-conjugated anti-goat IgG F(ab')₂ and FITC-conjugated mAbs as indicated. In BM, PB, and peritoneal cells, FSC^{high}SSC^{high} populations representing myeloid lineage were gated and analyzed for mLMIR5 expression. In thymus, the FSC^{low}SSC^{low} populations representing lymphoid lineage were analyzed. (C) Single-cell suspensions were prepared from spleen. After B220⁺, CD3⁺, CD11b⁺, or CD11c⁺ cells were sorted by using FITC-conjugated Abs, these cells were stained as described in panel B. (D) Analysis of mLMIR5 expression on murine BM-derived cells. BMMCs, BmMDCs, BmpDCs, and BMMΦ were stained with control IgG or anti-mLMIR5 Ab followed by PE-conjugated anti-goat IgG F(ab')₂. The result of control or mLMIR5 staining is shown as a filled or bold-lined histogram, respectively. All the data are representative of 3 independent experiments.



highly expressed in BM and moderately in the lung and colon (Figure 1D). Further investigation of hematopoietic cells revealed that high expression levels of mLMIR5 were observed in myeloid cell lines, including mast, macrophage, and dendritic cell lines, as well as BM-derived cells, but not in T cell lines (Figure 1E,F). Before analyzing surface expression levels of mLMIR5, we confirmed the sensitivity and specificity of polyclonal anti-mLMIR5 Ab, which recognized the extracellular domain of mLMIR5. When Ba/F3 cells were transduced with Flag-tagged mLMIR5, this Ab efficiently detected mLMIR5 on the cell surface, whose expression was confirmed by using anti-Flag mAb (Figure 2A), and anti-mLMIR5 Ab did not detect LMIR1, LMIR2, LMIR3, or LMIR4 transduced into Ba/F3 cells (Figure S1, available on the *Blood* website; see the Supplemental Materials link at the top of the online article). In addition, this polyclonal Ab and anti-Flag Ab gave a similar pattern of several bands in the Western blot of the immunoprecipitates derived from Flag-tagged mLMIR5-transduced Ba/F3 cells. Endogenous mLMIR5 in BMMCs was also detected as a similar pattern. These results confirmed the specificity of this polyclonal Ab raised against mLMIR5 (Figure S3). Surface staining of hematopoietic cell lines with anti-mLMIR5 Ab displayed the results consistent with those from RT-PCR (Figures 1E,

S2); A20 cells among the B-cell lines were found to express LMIR5 in both mRNA and protein levels. We then stained a variety of hematopoietic cells using this anti-mLMIR5 Ab. When gated in the population (FSC^{high}SSC^{high}), immature granulocytes (Gr-1^{high}) in BM and macrophages (CD11b^{high}) in peritoneal cells displayed higher expression levels of mLMIR5, while mature granulocytes (Gr-1^{high}) in PB and dendritic cells (CD11c^{high}) in spleen showed detectable but lower expression levels as compared with immature granulocytes. However, neither B cells (B220^{high}) in spleen nor T cells (CD3^{high}) in spleen and thymus expressed mLMIR5 on their surfaces (Figure 2B,C). In addition, mLMIR5 was expressed in BM-derived cells such as BMMCs, BmMDCs, BmpDCs, and BMMΦ (Figure 2D). LMIR5 expression was also confirmed in several types of mast cells, including peritoneal mast cells and FLCMs (Figure 2D; data not shown). Collectively, mLMIR5 was mainly expressed in myeloid cells.

mLMIR5 associates strongly with DAP12 and to a lesser extent with DAP10 in mLMIR5-transduced cells

The presence of a positively charged residue (lysine) in the transmembrane suggested that LMIR5 associated with adaptor




Figure 3. Association of LMIR5 with adaptor molecules such as DAP10, DAP12, and FcR γ . (A,B) Ba/F3 cells were cotransduced with a Myc-tagged mLMIR5 or hLMIR5 and either a Flag-tagged DAP10, DAP12, FcR γ , or mock. (A) Cell-surface expression levels of mLMIR5 (top row) or hLMIR5 (bottom row) were analyzed by flow cytometry by staining cells with control mouse IgG1 or anti-Myc mAb, followed by FITC-conjugated anti-mouse Ig polyclonal Ab. The result of LMIR5 staining in the presence or absence of indicated adaptor molecule was represented by bold- or thin-lined histograms, respectively, while that of control staining was represented by a filled histogram. (B) Lysates of transduced-Ba/F3 cells were immunoprecipitated with anti-mLMIR5 Ab, anti-Myc Ab, or anti-Flag mAb, and then immunoblotted with anti-Flag mAb or anti-Myc mAb. (C) Lysates of mLMIR5-transduced BMMCs were immunoprecipitated with control IgG or anti-mLMIR5 Ab, and then immunoblotted with anti-DAP12 Ab or anti-Flag mAb.


molecules—such as DAP10, DAP12, and FcR γ —containing a negatively charged residue within the transmembrane domain. To test this, we generated Ba/F3 cells cotransfected with retroviruses expressing a Myc-tagged mLMIR5 or hLMIR5 together with either a Flag-tagged DAP10, DAP12, FcR γ , or mock. Transduction of either mLMIR5 or hLMIR5 did not alter the expression levels of DAP10 and DAP12 mRNA when tested by real-time PCR (data not shown). Staining of these transfectants with anti-Myc mAb revealed that surface expression levels of mLMIR5 were significantly lower than those of hLMIR5 when LMIR5 was expressed alone. Surface expression levels of mLMIR5 were weakly or strongly elevated by DAP10 transduction or DAP12 transduction, respectively, while those of hLMIR5 were elevated by DAP10 as efficiently as by DAP12 (Figure 3A). The transduction of FcR γ did not influence the surface expression levels of mLMIR5 and hLMIR5 (Figure 3A). To confirm the physical association of mLMIR5 with either DAP10 or DAP12, we performed coimmunoprecipitation experiments; DAP12, but not DAP10, was coimmunoprecipitated with mLMIR5 probably because mLMIR5 more strongly associated with DAP12 compared with DAP10. On the other hand, total expression levels of mLMIR5 were elevated by the transduction of either DAP10 or DAP12, suggesting that these adaptors stabilized mLMIR5. When similar experiments were conducted on hLMIR5, both DAP10 and DAP12 were coimmuno-

precipitated with hLMIR5 (Figure 3B). Furthermore, coimmunoprecipitation of endogenous DAP12 with transduced mLMIR5 was observed in BMMCs (Figure 3C). In conclusion, mLMIR5 was capable of associating strongly with DAP12 and to a lesser extent with DAP10, at least in mLMIR5-transduced cells.

Cross-linking of mLMIR5 induces the activation of mast cells

Since mLMIR5 was highly expressed in mast cells, we analyzed the activating functions of mLMIR5 in BMMCs. To obtain strong activation, mLMIR5 was transduced into BMMCs. When mLMIR5 was engaged by anti-mLMIR5 Ab, but not control Ab, in mLMIR5-transduced BMMCs, strong activation of ERK, p38, and Akt was recognized by using phospho-specific Abs, indicating a cellular activation in mast cells stimulated by LMIR5 cross-linking (Figure 4A). Mast cells, when activated by Fc ϵ R1 aggregation, cause a variety of activation events such as cytokine/chemokine production and degranulation characterized by histamine release.^{1,3,25,36-38} Therefore, we performed experiments to examine whether similar activation events were induced by mLMIR5 engagement. In line with cellular activation, mLMIR5-transduced BMMCs stimulated by anti-mLMIR5 Ab, but not control Ab, produced IL-6, TNF- α , and MCP-1 (Figure 4B), and adhered efficiently to fibronectin or fibrinogen (Figure 4C). On the other hand, degranulation or cell

Figure 4. Cross-linking of mLMIR5 induced the phosphorylation of several signaling molecules in mLMIR5-transduced mast cells, resulting in cytokine/chemokine production, cell adhesion, histamine release, and cell survival. (A) BMMCs transduced with mLMIR5 were stimulated with either control IgG or anti-mLMIR5 Ab for 3 or 15 minutes. Cell lysates were subjected to immunoblotting with either anti-phospho-p44/42 MAPK (pERK1/2), anti-phospho-p38 MAPK (pp38), or anti-phospho-Akt (pAkt) Ab. Equal loading was evaluated with by reprobing the immunoblots with Abs specific for ERK1/2, p38, or Akt. (B) BMMCs transduced with mLMIR5 were incubated with PBS, control IgG, or anti-mLMIR5 Ab for 12 hours. IL-6, TNF- α , and MCP-1 released into the culture supernatants were measured by ELISA. (C) BMMCs transduced with mLMIR5 in FN- or FB-coated plates were stimulated with PBS, control IgG, or anti-mLMIR5 Ab for 60 minutes. Adherent cells were measured as described in "Measurement of cytokines and histamines and adhesion assay." (D) FLMCs transduced with mLMIR5 were incubated with PBS, control IgG, or anti-mLMIR5 Ab for 50 minutes. Alternatively, anti-TNP IgE-sensitized cells were incubated with TNP-BSA for 50 minutes. Histamine released in the culture supernatants was measured. (E) FLMCs transduced with mLMIR5 were incubated with either PBS, control IgG, anti-mLMIR5 Ab, or IgE (SPE-7) in the absence of IL-3. At indicated time points, cells were stained with PE-labeled annexin V to monitor apoptosis. Cells incubated in the presence of IL-3 were also analyzed. All data points correspond to the mean and the standard deviation (SD) of 4 independent experiments. Statistically significant differences are shown. * $P < .05$.



survival effect was significant but weak in mLMIR5-transduced BMMCs stimulated by anti-mLMIR5 Ab (data not shown). Importantly, mLMIR5-transduced FLMCs in response to anti-mLMIR5 Ab stimulation efficiently released histamine and showed an antiapoptotic effect under IL-3-depleted conditions, thus demonstrating that engagement of endogenous mLMIR5 could also activate the cellular responses (Figure 4D,E).^{25,39,40} Taken together, mLMIR5 functioned as an activating receptor in mast cells.

DAP12 is required for the activation induced by mLMIR5 engagement as well as the sufficient surface expression of mLMIR5 under physiologic conditions

To determine which adaptor protein was a physiologic partner of mLMIR5, we analyzed surface expression levels of mLMIR5 in BM cells or BMMCs derived from wild-type (WT), *DAP10*^{-/-}, *DAP12*^{-/-}, or *FcR γ* ^{-/-} mice.^{20,22,23,28,29,41} As depicted in Figure 5A, surface expression levels of mLMIR5 in BM granulocytes derived only from *DAP12*-deficient mice were reduced when compared with those from other mice. On the other hand, surface expression levels of mLMIR5 in BMMCs were strongly or

moderately reduced by *DAP12* or *DAP10* deficiency, respectively (Figure 5B). To further address the dependency of activating events caused by mLMIR5 aggregation on each adaptor protein, mLMIR5 was transduced into these BMMCs. The transduced cells exhibited comparable expression levels of Fc ϵ R1 and c-kit in addition to transduced mLMIR5, irrespective of the deficiency of respective adaptor molecule (Figure 5C bottom row). Fc ϵ R1 expression was not detectable in FcR γ -deficient BMMCs as reported (Figure 5C top row).^{29,41} Importantly, *DAP12*- or *DAP10*-deficient BMMCs in response to mLMIR5 engagement exhibited negligible or weak, respectively, activation of ERK as compared with WT BMMCs (Figure 5D), in proportion to the decreased capacities of *DAP12*- or *DAP10*-deficient BMMCs to adhere to fibronectin (Figure 5E). Concurrently, we confirmed that adhesion levels caused by PMA stimulation were comparable among these transfectants, and that FcR γ -deficient BMMCs did not adhere in response to IgE because of the lack of Fc ϵ R1 on the cell surface, as expected (Figure 5E). Although the deficiency of adaptor molecules did not show any morphologic difference in mast cells (data not shown), real-time PCR analysis demonstrated significantly low expression levels




Figure 5. Analysis of BM cells and BMMCs derived from *DAP10*^{-/-}, *DAP12*^{-/-}, and *FcRγ*^{-/-} mice. (A,B) Surface expression levels of endogenous mLMIR5 on BM cells and BMMCs derived from WT, *DAP10*^{-/-}, *DAP12*^{-/-}, or *FcRγ*^{-/-} mice were analyzed as described in Figure 2. The mean fluorescent intensity (MFI) of mLMIR5 expression was indicated in BMMCs. (C) WT, *DAP10*^{-/-}, *DAP12*^{-/-}, or *FcRγ*^{-/-} BMMCs transduced with Flag-tagged mLMIR5 were stained with control IgG or anti-Flag mAb followed by FITC-conjugated anti-mouse Ig Ab to confirm transduced-mLMIR5 expression levels (bottom row). Phenotypic analysis of BMMCs was performed as described in materials and methods (top row). (D) Either WT, *DAP10*^{-/-}, *DAP12*^{-/-}, or *FcRγ*^{-/-} BMMCs transduced with mLMIR5 were stimulated with control IgG or anti-mLMIR5 Ab. The amount of phosphorylated ERK1/2 was analyzed as described in Figure 4A. Vertical lines have been inserted to indicate a repositioned gel lane. (E) Either WT, *DAP10*^{-/-}, *DAP12*^{-/-}, or *FcRγ*^{-/-} BMMCs transduced with mLMIR5 were stimulated on FN-coated plates. Percentages of adherent cells were estimated. All data points correspond to the mean and the SD of 3 independent experiments as indicated. (F) Relative expression levels of *DAP10*, *DAP12*, and *FcRγ* among WT, *DAP10*^{-/-}, *DAP12*^{-/-}, and *FcRγ*^{-/-} BM or BMMCs were estimated by using real-time PCR as described in "Gene expression analysis." The amount of expression was indicated relative to that in wild-type BM or BMMCs. Data are representative of 3 independent experiments.

(approximately 30%) of *DAP12* in *DAP10*-deficient BMMCs and decreased expression levels of *DAP10* (approximately 60%) in *DAP12*- or *FcRγ*-deficient BMMCs, when compared with those in WT BMMCs (Figure 5F right panel). On the other hand, expression levels of *DAP12* in *DAP10*-deficient BM were approximately 70% of those in WT BM (Figure 5F left panel). Considering the recent report that *DAP12* transcript levels were not altered by *DAP10* deficiency,^{20,22} expression levels of *DAP12* might have been decreased during the course of differentiation of *DAP10*-deficient BMMCs in culture. Thus, attenuated activation induced by mLMIR5 cross-linking as well as reduced surface expression levels of mLMIR5 in *DAP10*-deficient BMMCs can be explained by the decreased expression levels of *DAP12* rather than by the deficiency of *DAP10*. In summary, *DAP12* plays a major role in maintaining surface expression levels of mLMIR5 under physiologic conditions and in transmitting activating signals induced by mLMIR5 aggregation.

Different signaling pathways between mLMIR5 and hLMIR5

To explore whether the activating functions of hLMIR5 are also regulated by *DAP12*, Flag-tagged hLMIR5 was transduced into WT or *DAP12*-deficient BMMCs. Surprisingly, *DAP12* deficiency

did not inhibit but rather enhanced IL-6 production caused by hLMIR5 cross-linking (Figure 6A bottom row), while it completely abrogated that by mLMIR5 cross-linking (Figure 6A top row), notwithstanding equivalent amounts of cytokine production of WT and *DAP12*-deficient transfectants stimulated by PMA (Figure 6A). This was consistent with the finding that LMIR5 cross-linking induced strong activation of ERK in *DAP12*-deficient BMMCs transduced only with hLMIR5, but not mLMIR5 (Figure 6B), and that ERK activation induced by cross-linking of transduced hLMIR5 was rather enhanced in *DAP12*-deficient BMMCs in comparison with that of WT BMMC (Figure 6C). Since hLMIR5, but not mLMIR5, contained the putative phosphorylation site (Y188) in the cytoplasmic tail, we asked if this is related to *DAP12*-independent activation of mast cells stimulated by hLMIR5 cross-linking. Intriguingly, the phosphorylation of hLMIR5 was observed only in *DAP12*-deficient, but not WT, mast cells in response to hLMIR5 aggregation (Figure 6C). To further confirm that Y188 of hLMIR5 was indeed phosphorylated, we transduced either mock, Flag-tagged hLMIR5, or Flag-tagged hLMIR5 (Y188F) into WT BMMCs. As demonstrated in Figure 6D, stimulation of BMMCs with pervanadate induced tyrosine phosphorylation of hLMIR5, but not hLMIR5 (Y188F), suggesting that Y188 was a




Figure 6. Cross-linking of human LMIR5 induced the activation via phosphorylation of Y188 in its cytoplasmic region in DAP12-deficient BMMCs. (A) WT or DAP12^{-/-} BMMCs transduced with a Flag-tagged mLMIR5 were stimulated with control IgG, anti-mLMIR5 Ab, or PMA (top panels), while WT or DAP12^{-/-} BMMCs transduced with Flag-tagged hLMIR5 were stimulated with control IgG, anti-Flag mAb, or PMA (bottom panels). IL-6 released into the culture supernatants was measured by ELISA. All data points correspond to the mean and the SD of 4 independent experiments. (B) DAP12^{-/-} BMMCs transduced with either a Flag-tagged mLMIR5 or hLMIR5 were stimulated with the indicated Abs for 3 minutes. The amount of phosphorylated ERK1/2 was analyzed as described. (C) WT or DAP12^{-/-} BMMCs transduced with Flag-tagged hLMIR5 or WT BMMCs transduced with Flag-tagged hLMIR5 (K158Q) were incubated with the indicated Abs. Immunoprecipitates of cell lysates with anti-Flag mAb were immunoblotted with anti-phosphotyrosine mAb (4G10) or anti-Flag mAb. Total cell lysates were also analyzed to detect the amount of phosphorylated ERK1/2. Vertical lines have been inserted to indicate a repositioned gel lane. (D) BMMCs transduced with Flag-tagged hLMIR5, hLMIR5 (Y188F), or mock were stimulated with the indicated Ab for 3 minutes or with 100 μ M pervanadate (PV) for 10 minutes. Immunoprecipitates of cell lysates with anti-Flag mAb were blotted with antiphosphotyrosine mAb (4G10) or anti-Flag mAb. Vertical lines have been inserted to indicate a repositioned gel lane. (E-H) WT (E) or DAP12^{-/-} (F) DAP10^{-/-} (G), or DAP12^{-/-} DAP10^{-/-} (H) BMMCs transduced with Flag-tagged hLMIR5, hLMIR5 (K158Q), hLMIR5 (Y188F), or hLMIR5 (K158Q) (Y188F) were stimulated with control IgG or anti-Flag mAb. IL-6 released into the culture supernatants was measured by ELISA. All data points correspond to the mean and the SD of 3 independent experiments. K158Q, Y188F, or KQYF indicate hLMIR5 (K158Q), hLMIR5 (Y188F), or hLMIR5 (K158Q) (Y188F), respectively. (I) DAP12^{-/-} DAP10^{-/-} BMMCs transduced with Myc-tagged hLMIR5 (Y188F) were transfected with Flag-tagged DAP10, DAP12, or mock. Immunoprecipitates of cell lysates were immunoblotted with anti-Flag mAb (left panel). These cells were stimulated with control IgG or anti-Myc mAb. IL-6 released into the culture supernatants was measured by ELISA. All data points correspond to the mean and the SD of 3 independent experiments. Statistically significant differences are shown. **P* < .05.

major phosphorylation site in hLMIR5 (Figure 6D). Interestingly, when hLMIR5 (K158Q)-transduced WT BMMCs were stimulated by hLMIR5 cross-linking, hLMIR5 (K158Q) was strongly phosphorylated (Figure 6C), suggesting that hLMIR5-mediated Y188 phosphorylation could be induced by adaptors that associate with hLMIR5 not through K158. To clarify whether phosphorylation of Y188 is required for cytokine production of mast cells caused by hLMIR5 engagement in the presence or absence of DAP12, we transduced hLMIR5 or hLMIR5 (Y188F) into DAP12-deficient BMMCs as well as WT BMMCs. As depicted in Figure 6E,F, the replacement of Y188 with phenylalanine (F) had no effect on cytokine production of WT BMMCs in response to anti-Flag mAb stimulation (Figure 6E), but abrogated that of DAP12-deficient BMMCs (Figure 6F). Altogether, these data strongly suggest that downstream of hLMIR5 there exists Y188 phosphorylation-independent and -dependent pathways in the presence and absence of DAP12, respectively.

Since DAP10 also associated with hLMIR5, we next examined the role of DAP10 in hLMIR5-mediated cytokine production of BMMCs. After hLMIR5 or hLMIR5 (Y188F) was transduced into either DAP10- or DAP10/DAP12 double-deficient BMMCs, similar experiments were performed. Surprisingly, cross-linking of hLMIR5 induced cytokine production even in the absence of both DAP12 and DAP10, suggesting the existence of unidentified adaptors of hLMIR5 (Figure 6H). Disruption of Y188 reduced, but did not abrogate, cytokine production of DAP10/DAP12 double-deficient BMMCs, indicating the existence of Y188 phosphorylation-independent and -dependent signaling pathways (Figure 6H). Transduction of DAP10 or DAP12 into hLMIR5 (Y188F)-expressing DAP10/DAP12-double deficient BMMCs enhanced cytokine production weakly or strongly, respectively, suggesting that DAP12 mainly contributed to Y188 phosphorylation-independent signaling (Figure 6I). To further characterize adaptors of hLMIR5, we examined if the replacement of K158 affected hLMIR5-mediated cytokine production. Intriguingly, the disruption of K158 did not affect cytokine production of WT BMMCs, but dampened that of DAP12-deficient BMMCs, while the disruption of both K158 and Y188 completely abrogated cytokine production irrespective of the absence of DAP10 or DAP12 (Figure 6E-H).

Cross-linking of endogenous mLMIR5 on FLMCs induced a Syk-dependent activation, resulting in cytokine production and adhesion

As mentioned, FLMCs were strongly activated in response to transduced mLMIR5 engagement compared with BMMCs. Next, we tested whether endogenous mLMIR5 could also activate FLMCs. As demonstrated in Figure 7A, activation of ERK was detected in WT FLMCs stimulated by anti-mLMIR5 Ab, but not by control Ab. This ERK activation was severely inhibited in Syk-deficient FLMCs.²⁷ In accordance with this, IL-6 production and adhesive property were observed only in WT but not Syk-deficient FLMCs stimulated by engagement of endogenous mLMIR5, although PMA stimulation induced comparable levels of cytokine production and adhesion between WT and Syk-deficient FLMCs (Figure 7B,C). Altogether, aggregation of endogenous mLMIR5 in FLMCs induced Syk-dependent activation of mast cells, resulting in cytokine production and adhesion.




Figure 7. Cross-linking of endogenous mLMIR5 induced the activation of FLMCs. (A) WT or Syk-deficient FLMCs were stimulated with control IgG or anti-mLMIR5 Ab. The amount of phosphorylated ERK1/2 was measured as described. (B,C) IL-6 production (B) and percentage of adherent cells (C) were analyzed as described. All data points correspond to the mean and the SD of 4 independent experiments. Statistically significant differences are shown. * $P < .05$.

Discussion

In the present study, we characterized mLMIR5/CLM-7 as a novel member of LMIRs. The structure of mLMIR5 was typical of an activating receptor. mLMIR5 showed a higher homology with the paired receptors LMIR3/CLM-1 and LMIR4/CLM-5 as compared with another pair, LMIR1/CLM-8 and LMIR2/CLM-4, in the sequence of the Ig-like domain. Accordingly, LMIR5 would function as a counterpart of LMIR3 in the absence of LMIR4. Analysis using specific Ab against mLMIR5 revealed that mLMIR5 was mainly expressed in myeloid cells like other activating LMIRs, including LMIR2 and LMIR4, although there existed several differences; for example, LMIR4 or LMIR5 was highly expressed in mature or immature granulocytes, respectively.^{6,7,14} Thus, these activating receptors of the LMIR family displayed differing expression profiles among different stages of myeloid cells. In addition, high expression levels of mLMIR5 in colon and lung tissues may indicate that mLMIR5 is involved in mucosal immunity, possibly giving a clue to finding the ligands for mLMIR5.

A positively charged residue (lysine) in the transmembrane domain led us to postulate the association of mLMIR5 with ITAM- or the related activating motif-bearing adaptor proteins.^{15-19,23,42} Our data indicated that mLMIR5 was mainly associated with DAP12 to maintain its surface expression levels under in vivo and in vitro physiologic conditions. However, it was noted that DAP10, when overexpressed, up-regulated mLMIR5 at surface expression